Scalper1 News
Big-cap biotech Biogen Idec (BIIB) reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street’s expectations, but the stock was down more than 1% in early trading in the stock market today. Biogen said revenue rose 50.5% over the year-earlier quarter, to $2.13 billion, beating analysts’ consensus of $2 billion. But earnings per share of $2.47, up 25%, missed consensus of $2.56. The company, however, noted that included a $118 Scalper1 News
Scalper1 News